Infinimmune Announces Partnership with Grid Therapeutics to Conduct Deep Sequencing of B Cells for Oncology Antibody Drug Discovery in Non-Small Cell Lung Cancer (NSCLC)

On December 19, 2023, Infinimmune, a biotechnology company pioneering new methods for antibody drug discovery and development, announced a partnership with Grid Therapeutics (“Grid”), a clinical-stage biotechnology company that focuses on human-derived antibodies, to collaborate in identifying new antibody drug candidates for non-small cell lung cancer(NSCLC). The partnership will use Infinimmune’s Anthrobody™ drug discovery platform. Infinimmune’s therapeutic pipeline is built on antibodies that are complete, encompassing the full binding and effector regions of both chains. These are produced by human immune systems, distinct from those derived from model organisms, display libraries, or computational algorithms. During the course of the collaboration, the two companies will jointly study the antibody repertoire from a large cohort of NSCLC patients and control patients, who were selected on the basis of their clinical status and response to standard of care chemotherapies and immunotherapies. This will enable Grid and Infinimmune to prioritize their discovery approach using clinical information to understand differences and similarities between the antibody responses of individuals in response to lung cancer progression.

Login Or Register To Read Full Story